Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.

This document has been updated: version 15 March 2022.

For translations of this document in other languages, click here.

Related links:

• Background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG)
• GRADE and ETR tables